December 2021:

Webinar: What it Will Take for a Canadian Pediatric Consortium To Be Successful. A presentation by pediatric cancer research Advocates on how the Canadian childhood cancer community worked together to achieve this $30 million promise from the federal government and how we all must continue to work together to make this successful.

May 2021:

Thank you to the Federal Government for allocating $30 million in the 2021 Federal Budget for childhood cancer research. Ac2orn formally thanks Prime Minister Trudeau for his leadership to help fund pivotal research in pediatric oncology. Press Release (PDF)

September 18, 2018:

With the Health Canada approval of the chimeric antigen receptor T cell (CAR-T) therapy, Kymriah (tisagenlecleucel/CTL019), Ac2orn encourages the provincial health funding agencies to finalize their funding agreements for Kymriah to add it to the provincial formularies. Press Release (PDF)

September 6, 2018:

Ac2orn congratulates Novartis for the approval of Kymirah by Health Canada, the first Canadian approval of a chimeric antigen receptor T cell (CAR T cell) therapy, for relapsed and refractory acute lymphoblastic leukemia (ALL). Press Release (PDF)

June 6, 2018:

Over 30 leading pediatric oncologists and researchers, and 31 cancer organizations from across North America, are shedding light on the inequitable access to promising early phase clinical trials for Canadian children, adolescents and young adults (CAYA) with cancer and offering solutions to ensure no child gets left behind. Authored by Advocacy for Canadian Childhood Oncology Research Network (Ac2orn), with assistance from the C17 Council and Helena’s Hope: Pathways to More Kids Surviving Cancer, the proposal “Improving Outcomes for Canadian Children, Adolescents, and Young Adults with Cancer: A proposal for a working relationship with Health Canada”, provides actionable feedback from researchers and clinicians across the country.